Researchers have successfully tested a powerful gene therapy, delivered directly into the heart, to reverse heart failure in large animal models. Researchers at the Cardiovascular Research Center at ...
Evidence that 13-M, a unique small molecule disruptor of adrenergic SERCA2 activity reduces infarct size and preserves cardiac function Oslo, Norway – 29 August 2023 - Serca Pharmaceuticals, a ...
Researchers are poised to begin human clinical trials of a novel gene therapy to treat a major cause of heart disease by shrinking enlarged hearts in order to improve blood flow and cardiac function.
Researchers at the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai have successfully tested a powerful gene therapy, delivered directly into the heart, to reverse heart ...
Evidence that 13-M, a unique small molecule disruptor of adrenergic SERCA2 activity reduces infarct size and preserves cardiac function The findings presented suggest that specifically blocking the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results